This preclinical study suggests aspirin as a potent anti-migratory agent to improve the therapeutic index of highly metastatic NSCLCs in which EMT, a pre-requisite for cancer cell migration, being programmed by the conjoint effort of both K-ras and NFκB pathways. Here, NFKB1 is linked to cancer.